ME — 23andMe Holding Co. Share Price
0.000.00%
Last trade - 00:00- $214.03m
- -$28.39m
- $299.49m
- 47
- 61
- 34
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.57 | ||
| Price to Tang. Book | 1.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.86 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -116.12% | ||
| Return on Equity | -92.53% | ||
| Operating Margin | -217.3% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 440.9 | 305.46 | 243.92 | 271.89 | 299.49 | 217.05 | 265.04 | -9.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Directors
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 16th, 2021
- Public Since
- October 6th, 2020
- No. of Shareholders
- 284
- No. of Employees
- 769
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 482,916,636
- Address
- 349 Oyster Point Boulevard, SOUTH SAN FRANCISCO, 94080
- Web
- https://investors.23andme.com/
- Phone
- +1 6509386300
- Auditors
- KPMG LLP
Upcoming Events for ME
23andMe Holding Co. Annual Shareholders Meeting
Similar to ME
Acadia Healthcare
NASDAQ Global Select Market
Accolade
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
FAQ
What is the 23andMe Holding Co. share price?
As of Today at 19:00 UTC, shares in 23andMe Holding Co. are trading at $0.44. This share price information is delayed by 15 minutes.
How has the 23andMe Holding Co. share price performed this year?
Shares in 23andMe Holding Co. last closed at $0.44 and the price had moved by -80.65% over the past 365 days. In terms of relative price strength the 23andMe Holding Co. share price has underperformed the S&P500 Index by -84.37% over the past year.
What are the analyst and broker recommendations for 23andMe Holding Co.?
The overall consensus recommendation for 23andMe Holding Co. is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the 23andMe Holding Co. dividend yield?
23andMe Holding Co. does not currently pay a dividend.
Does 23andMe Holding Co. pay a dividend?
23andMe Holding Co. does not currently pay a dividend.
When does 23andMe Holding Co. next pay dividends?
23andMe Holding Co. does not currently pay a dividend.
How do I buy 23andMe Holding Co. shares?
To buy shares in 23andMe Holding Co. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 23andMe Holding Co.?
As of the previous close price of $0.44, shares in 23andMe Holding Co. had a market capitalisation of $214.03m.
Where are 23andMe Holding Co. shares listed?
Here are the trading details for 23andMe Holding Co.:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ME
What kind of share is 23andMe Holding Co.?
Based on an overall assessment of its quality, value and momentum 23andMe Holding Co. is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 23andMe Holding Co. share price forecast for 2024?
The analyst consensus target price for shares in 23andMe Holding Co. is $1.43. That is 222.65% above the last closing price of $0.44.
Analysts covering 23andMe Holding Co. currently have a consensus Earnings Per Share (EPS) forecast of -$1.10 for the next financial year.
What is the trend in the 23andMe Holding Co. share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 23andMe Holding Co.. Over the past six months, its share price has underperformed the S&P500 Index by -55.34%.
As of the last closing price of $0.44, shares in 23andMe Holding Co. were trading -53.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 23andMe Holding Co. PE Ratio?
The 23andMe Holding Co. PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 23andMe Holding Co.?
We do not have data on 23andMe Holding Co.'s directors